DelveInsight’s “Cytokine Release Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cytokine Release Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Cytokine Release Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cytokine Release Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cytokine Release Syndrome: An Overview
Cytokine Release Syndrome (CRS) is an acute systemic inflammatory response characterized by fever and multiple organ dysfunction associated with CAR T-cell therapy, therapeutic antibodies, haploidentical allogeneic transplantation, etc. Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neuropsychiatric syndrome that can occur in some patients treated with immunotherapy and may or may not accompany CRS.
CRS’s complex signs and symptoms result from the effects of cytokines released by the CAR T cells once engaged with the target. Serum levels of inflammatory cytokines are elevated, particularly IL‐6. The severity of symptoms may correlate with the serum cytokine concentrations and the duration of exposure to the inflammatory cytokines.
Cytokine Release Syndrome Market Key Facts
The total Cytokine Release Syndrome market size in the United States accounted for USD 3.5 million in 2021 which is expected to rise during the study period (2019–2032).
In the EU5, the total Cytokine Release Syndrome market size was USD 0.8 million in 2021, which is expected to rise during the study period (2019–2032).
According to DelveInsight, in the year 2021, the total number of incident cases of cytokine release syndrome was 11,559 in the United States.
The highest number of total incident cases of cytokine release syndrome was observed in Germany among the EU5 countries with 8,222 cases in 2021 which are expected to grow during the study period, i.e., 2019–2032.
In the year 2021, the total number of incident cases of cytokine release syndrome was 3,792 in Japan.
Cytokine Release Syndrome Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Cytokine Release Syndrome pipeline therapies. It also thoroughly assesses the Cytokine Release Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Cytokine Release Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cytokine Release Syndrome Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Cytokine Release Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Cytokine Release Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Cytokine Release Syndrome Epidemiology, Segmented as –
Total Incident Cases of CRS in the 7MM [2019–2032]
CRS cases by CAR-T Therapies in the 7MM [2019–2032]
Grade-specific Cases of CRS in the 7MM [2019–2032]
CRS cases by Allogenic Transplant in the 7MM [2019–2032]
CRS cases by Bispecific Antibodies in the 7MM [2019–2032]
Cytokine Release Syndrome Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cytokine Release Syndrome market or expected to be launched during the study period. The analysis covers the Cytokine Release Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Cytokine Release Syndrome drugs based on their sale and market share.
The report also covers the Cytokine Release Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Cytokine Release Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cytokine Release Syndrome Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/cytokine-release-syndrome-market
Cytokine Release Syndrome Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cytokine Release Syndrome. Currently, Novartis is leading the therapeutics market with its Cytokine Release Syndrome drug candidates in the most advanced stage of clinical development.
Cytokine Release Syndrome Companies Actively Working in the Therapeutics Market Include
Incyte Corporation
Swedish Orphan Biovitrum (SOBI)
Genentech
Biocon Limited
Olatec Therapeutics LLC
Novartis Pharmaceuticals
And Many Others
Emerging and Marketed Cytokine Release Syndrome Therapies Covered in the Report Include:
Canakinumab: Novartis
Itacitinib: Incyte Corporation
Dapansutrile: Olatec Therapeutics LLC
Anakinra: Sobi
ACTEMRA/ROACTEMRA (tocilizumab): Genentech
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cytokine Release Syndrome Competitive Intelligence Analysis
4. Cytokine Release Syndrome Market Overview at a Glance
5. Cytokine Release Syndrome Disease Background and Overview
6. Cytokine Release Syndrome Patient Journey
7. Cytokine Release Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Cytokine Release Syndrome Treatment Algorithm, Current Treatment, and Medical Practices
9. Cytokine Release Syndrome Unmet Needs
10. Key Endpoints of Cytokine Release Syndrome Treatment
11. Cytokine Release Syndrome Marketed Therapies
12. Cytokine Release Syndrome Emerging Drugs and Latest Therapeutic Advances
13. Cytokine Release Syndrome Seven Major Market Analysis
14. Attribute Analysis
15. Cytokine Release Syndrome Market Outlook (In US, EU5, and Japan)
16. Cytokine Release Syndrome Companies Active in the Market
17. Cytokine Release Syndrome Access and Reimbursement Overview
18. KOL Views on the Cytokine Release Syndrome Market
19. Cytokine Release Syndrome Market Drivers
20. Cytokine Release Syndrome Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Insulin Glargine Biosimilar
“Insulin Glargine Biosimilar Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in the Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
